Insights
Insights From Our Experts
Articles
A Deeper Dive into Pharmatizing AI & What It Will Mean to the Future of Commercialization
For the past 4 years, we have talked about our commitment to “Pharmatize AI” to deliver true change for the industry. The time to lead is now. We’re at a transformation moment where, through the power…
Reimagining Pharma Commercialization with AI Agents
AI isn’t just a tool—it’s a team member. That’s the bold vision that my colleague, Scott Snyder, Chief Digital Officer at EVERSANA, shared in a recent interview with pharmaphorum. Scott’s interview does a great job highlighting…
Unveiling the Real DTP: Beyond Common Misconceptions
Posted by
Hari Ramachandran on September 12, 20259/12/25
When most people hear “Direct-to-Patient” (DTP), they immediately think of a video call with a doctor—a telehealth visit. But in reality, DTP encompasses much more than just virtual consultations. DTP represents a strategic reorientation of existing…
Ready, Set, Simplify: PV Without the Hassle
Pharmacovigilance (PV) is a discipline layered with regulations, legacy systems, complex workflows, and global standards. Most PV platforms feel like they were built for experts, not users. Too often, PV systems become increasingly complex with every…
The Most-Favored-Nation Model: Global Benchmark or Global Risk?
In response to growing public concern over rising drug costs, U.S. policymakers have proposed a Most-Favored-Nation (MFN) pricing model, linking domestic drug prices to those negotiated in other developed countries, many of which operate under tightly…
The Evolution of the 340B Rebate Model: Maintaining Patient Access while Minimizing Duplicate Discounts
The 340B program has struggled with implementing effective oversight of the covered entities since the program was established in 1992. Diversion and duplicate discounts are the primary issues that manufacturers face. Diversion typically happens when a…
2026 CMS Proposed Rule: BFSF Changes and Potential Risks for Pharma Manufacturers
CMS released its 2026 Proposed Rule this summer, outlining payment and coverage policy updates for Medicare Part B and related programs. For pharmaceutical manufacturers, the most significant development is the long-awaited clarification on bona fide service…
Navigating OBBBA: Why a Strong GP Team is Essential for Pharma Compliance
On July 4, 2025, the One Big Beautiful Bill Act (OBBBA) was signed into law, marking a significant shift in Medicaid, Medicare, and federal drug pricing policy. While broad in scope, its provisions have direct consequences…
The Future of Personalized, Measurable MSL Engagement
In today’s complex healthcare landscape, Medical Science Liaisons (MSLs) are under pressure to deliver more than trusted relationships. They must provide personalized, data-driven engagement that creates measurable value. While 58% of healthcare professionals rank MSL interactions…
Rewriting the Rules of Pharma Commercialization: Why the AI Agency Is the Catalyst Life Sciences Has Been Waiting For
Scientific innovation is accelerating. But commercialization? It’s stuck in the past — fragmented, reactive and increasingly unsustainable. Learn why the AI Agency is the catalyst life sciences commercialization has been waiting for in this POV. Faruk Capan,…